Eli Lilly (LLY)Simplify Asset Management Inc. reduced its stake -1,988 shares

15K

Shares reported · -1,988 vs prior quarter

0.25%

Disclosed portfolio weight

$17.6M

Reported value

Holdings as of

Jun 30, 2026

Filed

Jul 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 2, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
2. Jan 2, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
3. Mar 27, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
4. Jun 9, 2026FDAFDA drug approval: Ebglyss
5. Jun 10, 2026Insider · Their largest sale since 2022Officer sold ~$2.88M of LLY shares in the open market
6. Jun 10, 2026Congress · 1 personMembers of Congress: 2 purchases
7. Jul 1, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
8. Jul 10, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
9. Jul 13, 2026FDAFDA drug approval: Verzenio
10. Jul 14, 2026FDAFDA drug approval: Retevmo
11. Jul 14, 2026FDAFDA drug approval: Retevmo

What came next

1. Jul 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.6%
2. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
3. Aug 7, 2026InsiderOfficer sold ~$5.95M of LLY shares in the open market
4. Aug 10, 2026Insider · Their largest sale since 2014Officer sold ~$2.37M of LLY shares in the open market
5. Aug 17, 2026Federal contract · $5K obligatedDepartment of Veterans Affairs awarded Eli Lilly: $4.5K obligated to date
6. Aug 17, 2026Insider · Their largest sale since 2022Officer sold ~$7.64M of LLY shares in the open market
7. Aug 26, 2026FDAFDA drug approval: Zepbound
8. Aug 27, 2026FDAFDA drug approval: Mounjaro
9. Aug 27, 2026FDAFDA drug approval: Mounjaro
10. Sep 18, 2026FDAFDA drug approval: Inluriyo
11. Sep 18, 2026FDAFDA drug approval: Verzenio
12. Sep 23, 2026FDAFDA drug approval: Onswik
13. Sep 25, 2026FDAFDA drug approval: Olumiant

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

How this filing works

• SEC Form 13F

Other disclosures at Eli Lilly

• SEC Form 144Oct 7, 2026
• USAspending.gov award recordSep 1, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 18, 2026

Everything OQRO holds on this company is on its LLY page.